TGETs not only inhibit the tyrosine kinase activity of EGFR but also have inhibitory effects on multiple other targets, allowing for a more comprehensive blockade of tumor cell signaling pathways, effectively inhibiting tumor cell growth and spread 35. The gene discussed is EGFR; the disease is neoplasm.